About LifT Biosciences
LIfT Biosciences is a Biotech bringing to market a 1st in class Immuno-Oncology Cell Therapy called N-LIfT that has the game-changing potential to destroy all solid tumours irrespective of mutation or strain. N-LIfT (Neutrophil Only Leukocyte Infusion Therapy) builds on 18 years of ground breaking research into innate cancer immunity by the renown co-founder Prof Zheng Cui. Our vision is to develop the world’s first cell bank of mass produced ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for curing all solid tumours.
LIfT BioSciences N-LIfT therapy platform is an off-the-shelf allogeneic patented product that we mass produce from exceptional stem cells from donors with exceptional immunity. LIfT BioSciences are the industry leaders in neutrophil ATMPs (currently only), the team is made-up of combination of experienced industry leaders and the leading experts. LIfT has already proven to be 100% curative in mice and with promising human data in an FDA approved safety trial showing upto 80% tumour necrosis in a mix of late stage carcinoma patients even at low dose.
Our vision is to develop the world’s first cell bank of ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for all solid tumours, with an initial focus on high unmet need orphan tumours such as those found in the lung, liver and pancreas.
State of Ownership
Business Development Executive, Nature Publishing Group, Springer Nature